AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03328832
Drug: Topical tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule
Trial: NCT03328832
Drug: rivaroxaban (10mg)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
Trial: NCT00049257
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered Day 1 of each cycle. AUC=6.
Trial: NCT00049257
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered Days 1, 8, and 15 of each cycle. 100mg/m2
Trial: NCT00439101
Drug: Megstrol Acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
Trial: NCT02559973
Drug: RBP-6000
RxNorm normalized name: COCAINE ESTERASE (RBP-8000)
DrugBank: COCAINE ESTERASE (RBP-8000) (DB19225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
Trial: NCT02559973
Drug: SUBOXONE Sublingual Film
RxNorm normalized name: buprenorphine / naloxone Sublingual Film [Suboxone]
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
Trial: NCT02799589
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
Trial: NCT02799589
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
Trial: NCT00841087
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
Trial: NCT00841087
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Injection subcutaneously at bedtime
Trial: NCT00841087
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injection subcutaneously immediately before each meal.
Trial: NCT01060254
Drug: JNJ-42160443
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
Trial: NCT01949129
Drug: VP16
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
Trial: NCT01949129
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2x5 mg/kg BW, 1 day
Trial: NCT01949129
Drug: Treosulfan
RxNorm normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 14g/m² BS, 3 days
Trial: NCT01949129
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m² BS, 5 days
Trial: NCT01949129
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iV, dosage according therapeutic drug monitoring, 4 days
Trial: NCT01949129
Drug: ATG Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
Trial: NCT00374517
Drug: Pimonidazole hydrochloride
RxNorm normalized name: Pimonidazole
DrugBank: Pimonidazole (DB12485)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01079364
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
Trial: NCT01079364
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
Trial: NCT01079364
Drug: Premixed insulin (Insulin Aspart 30/70 )
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
Trial: NCT01514721
Drug: Travoprost/Timolol Maleate BAK-Free Fixed Combination
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
Trial: NCT00132301
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy agent
Trial: NCT00132301
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: steroid in combination with chemotherapy agent
Trial: NCT04096105
Drug: CC-93538
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose CC-93538 SC
Trial: NCT03345303
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib Injectable Solution
Trial: NCT02012218
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02691026
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01371058
Drug: high maintenance clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
Trial: NCT01371058
Drug: routine dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
Trial: NCT03186625
Drug: Compound Panax Notoginseng Granule
RxNorm normalized name: Panax notoginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months.
Trial: NCT01796288
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02623205
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
Trial: NCT02269696
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative metoprolol infusion.
Trial: NCT00833027
Drug: sitagliptin phosphate
RxNorm normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg/day - tablet for 24 weeks
Trial: NCT00169221
Drug: Iressa (Gefitinib)
RxNorm normalized name: Iressa
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: postoperative chemoradiotherapy with cisplatin + gefitinib
Trial: NCT02116842
Drug: 0.1% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural block in early labour.
Trial: NCT02116842
Drug: 0.075% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural block in early labour.
Trial: NCT00322842
Drug: G-CSF Plus Plerixafor
RxNorm normalized name: G-CSF
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Trial: NCT01890265
Drug: Pamrevlumab
RxNorm normalized name: Pamrevlumab
DrugBank: Pamrevlumab (DB14952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT01890265
Drug: Sub-Study: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone concomitant therapy will not be provided by the Sponsor.
Trial: NCT01890265
Drug: Sub-Study: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib concomitant therapy will not be provided by the Sponsor.
Trial: NCT00360178
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00553410
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
Trial: NCT00553410
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\> 36 mo) plus 1 x 12 mo in yr 5 -\> 48 months
Trial: NCT00087087
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02725242
Drug: Budesonide/formoterol (160/4.5 μg/d)
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
Trial: NCT03360760
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
Trial: NCT02418663
Drug: Fluid challenge (250 ml Lactated Ringer's solution)
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.~Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above
Trial: NCT03360760
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12g/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
Trial: NCT04248205
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
Trial: NCT01928628
Drug: Lercanidipine 10mg
RxNorm normalized name: lercanidipine 10 MG
DrugBank: Lercanidipine (DB00528)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01928628
Drug: Lercanidipine10mg /Valsartan 80mg
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01928628
Drug: Lercanidipine 10mg /Valsartan 160mg
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01928628
Drug: Lercanidipin 10mg Placebo
RxNorm normalized name: lercanidipine 10 MG
DrugBank: Lercanidipine (DB00528)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01928628
Drug: Lercanidipine10mg /Valsartan 80mg Placebo
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02913157
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally administered Hydroxychloroquine
Trial: NCT01541488
Drug: BI 1021958
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01541488
Drug: BI 1021958
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drinking solution / tablet
Trial: NCT02772978
Drug: Tolcapone
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
Trial: NCT02678299
Drug: PREBEN
RxNorm normalized name: AVOBENZONE 25.6 mg in 1 mL / HOMOSALATE 106.5 mg in 1 mL / OCTISALATE 42.6 mg in 1 mL / OCTOCRYLENE 23.43 mg in 1 mL / OXYBENZONE 51.12 mg in 1 mL TOPICAL SPRAY [Prebel Nude Protect SPF 70 Sunscreen]
DrugBank: Oxybenzone (DB01428)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02725242
Drug: Budesonide (400μg/d)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
Trial: NCT02071888
Drug: CB-839 and low dose dexamethasone
RxNorm normalized name: BroveX CB
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CB-839 and low dose dexamethasone
Trial: NCT02071888
Drug: CB-839, pomalidomide, and low dose dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CB-839, pomalidomide, and low dose dexamethasone
Trial: NCT01531712
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 / / 40mg/m2
Trial: NCT01531712
Drug: Tarceva
RxNorm normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg/day
Trial: NCT01531712
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg/m2 (only in QT)
Trial: NCT00101907
Drug: AMG 706
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
Trial: NCT00101907
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.
Trial: NCT00101907
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.
Trial: NCT01997515
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
Trial: NCT03647228
Drug: IONIS-ENaCRx
RxNorm normalized name: Ionis-enacrx
DrugBank: Cofirasersen (DB19037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
Trial: NCT00434967
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 32 mg oral tablet
Trial: NCT01207206
Drug: oral ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The group will be divided into two pain matched groups of 25 each. One group will receive Ketamine (K group) and the other placebo (P). Both the researchers and the patients will not know to which group they belong. Four days prior to the beginning of the research the patients will document, using an ad-hoc diary, in predetermined hours, four times a day the level (VAS) of pain, sedation and vomiting scores, and other side effects. Pain will be assessed using a Visual Analog Scale (VAS) (0-10).~The documentation will continue throughout the research period. The Ketamine or plaecebo will also be taken in a predetermined hours to avoid an effect of diurnal disruption on pain perception
Trial: NCT03464526
Drug: Orvepitant
RxNorm normalized name: Orvepitant
DrugBank: Orvepitant (DB12427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, once daily, oral
Trial: NCT02444572
Drug: Enoxaparin 4000 IU
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01107639
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Cisplatin 75 mg/m2 1h infusion d1, 22~* Cisplatin 25 mg/m2 1h infusion weekly x5
Trial: NCT00862446
Drug: Omegaven
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram/kg/day daily until on feeds
Trial: NCT01107639
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Docetaxel 75 mg/m2 1h infusion d1, 22~* Docetaxel 20 mg/m2 1/2h infusion weekly x5
Trial: NCT01848756
Drug: SNX-5422
RxNorm normalized name: SNX-5422
DrugBank: SNX-5422 (DB06070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
Trial: NCT00939913
Drug: intravenous NAC
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)
Trial: NCT00434967
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg oral tablet
Trial: NCT01047007
Drug: adavosertib 20 mg
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
Trial: NCT01047007
Drug: CDDP
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP 60 mg/m\^2 to 100 mg/m\^2 administered as an IV infusion on Day 1.
Trial: NCT01047007
Drug: adavosertib 65 mg
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
Trial: NCT00429143
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus given one day prior to transplant (HSCT).
Trial: NCT00429143
Drug: Mycophenolate Mofetil (MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MMF given one day prior to transplant (HSCT).
Trial: NCT00434967
Drug: Candesartan/HCT 32/25 mg
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002550
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002550
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00059202
Drug: Ursodeoxycholic Acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses
Trial: NCT04111614
Drug: Tofacitinib tablet
RxNorm normalized name: Tofacitinib Tablets
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of tofacitinib 5 mg tablet
Trial: NCT04111614
Drug: Tofacitinib Oral Solution
RxNorm normalized name: tofacitinib Oral Solution
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single 5 mL dose of tofacitinib oral solution (1 mg/mL)
Trial: NCT01260155
Drug: E5501
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions